Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.
Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.
Has no approved product, so spending is funded by selling shares, and any income would come from selling an approved drug or from a partnership. Cash runway and trial results decide how easily it can raise more.
Moat: none (IP / patents). Clinical-stage biotech targeting validated pathways with differentiated molecules, but no approved products.
Headquarters: Boulder, Colorado, US · Founded: 2020 · Employees: 60
Size Enliven Therapeutics (ELVN) is a United States Health Care company (Biotechnology) with a market value of $3.30B, the 1474th largest of 3,085 United States companies the cockpit tracks. Shares closed at $44.89 on 18 Nov 2026.
Performance Over six months the shares gained 7.2%, against +1.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Short interest Short interest is 14.0% of the free float (30 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$80,000 | -$263,000 | -$317,000 | -$297,000 | -$215,000 |
| EBITDA | -$135M | -$119M | -$104M | -$83.2M | -$38.6M |
| Net income | -$113M | -$104M | -$89.0M | -$71.6M | -$37.7M |
| Free cash flow | -$66.4M | -$70.5M | -$73.2M | -$61.4M | -$32.7M |
| Capital expenditure | $193,000 | $158,000 | $44,000 | $149,000 | $612,000 |
| Total debt | $1.31M | $399,000 | $0 | $335,000 | $323,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN | $3.30B | +7% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Puma Biotechnology PBYI | $373M | +3% | +9% | 11% | 1.2× | 0.1% |
| Ascentage Pharma Group International 6855.HK | $1.18B | -34% | +70% | -220% | 13.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ELVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.8% | -5.6% | 4th highest of 21 |
| 6-month return | +7.2% | +1.1% | 10th highest of 21 |
| Distance from 52-week high | -28.0% | -31.6% | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 11.8× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | 21.3× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 2.6× | -4.3% | +27.4% |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | 5.4× | n/a | n/a |